3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
9
gallium 68 PSMA-11
7
Specimen Handling
4
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
4
enzalutamide
2
bicalutamide
2
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
2
Standard of Care
2
Radiation
2
Positron Emission Tomography Computed Tomography
2
HhAntag691
2
Abiraterone Acetate
2
68Ga-DKFZ-PSMA-11
2
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
2
xentuzumab
1
trastuzumab biosimilar HLX02
1
tislelizumab
1
teprotumumab
1
tazemetostat
1
relugolix
1
pertuzumab
1
palbociclib
1
olaparib
1
niraparib
1
gallium citrate
1
eribulin
1
entrectinib
1
darolutamide
1
cobimetinib
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase EARLY_PHASE1
×
Prostatic Neoplasms
×
xentuzumab
×
Clear all
NCT05110495
2025-02-17
WINGMEN
University of Oxford
Phase EARLY_PHASE1
Completed
27 enrolled
9 charts